NEW YORK , Sept. 29, 2022 /PRNewswire/ — The Urticaria Drugs Market report has been added to Technavio’s offering. The urticaria drugs market value is anticipated to grow by USD 1.31 billion, at a CAGR of 10.35% during the forecast period. The urticaria drugs market report also offers information on several market vendors, including Allakos Inc., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., Genentech Inc., GlaxoSmithKline Plc, Johnson and Johnson, Meiji Holdings Co. Ltd., TerSera Therapeutics LLC, United BioPharma Inc., and Viatris Inc. among others. Request Free Sample Report.
Market Dynamics
One of the main factors boosting the market growth for urticaria medications is the rise in the prevalence of urticaria. A very common illness that leads to numerous medical consultations around the world is urticaria. The majority of patients receive inadequate care because of difficulties with medicine affordability and limited access to healthcare owing to social stigma, despite the fact that the prevalence is rising and is adversely affecting people’s quality of life.
The prevalence of the disease rises as a result. Additionally, the rising prevalence of allergic diseases and infections is one of the main risk factors for urticaria around the world. Due to their severe immunosuppression, these patients develop hives when mast cells and histamines are released. Buy Sample Report.
Company Profiles
The urticaria drugs market report provides complete insights on key vendors including Allakos Inc., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., Genentech Inc., GlaxoSmithKline Plc, Johnson and Johnson, Meiji Holdings Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Sanofi, TerSera Therapeutics LLC, Teva Pharmaceutical Industries Ltd., United BioPharma Inc., and Viatris Inc.
Competitive Analysis
The competitive scenario provided in the urticaria drugs market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.
Urticaria Drugs Market Vendors
-
Amneal Pharmaceuticals Inc.: The company offers oleris which is a bio-based seven-carbon linear chain saturated fatty acid suitable for sustainable design.
-
Aurobindo Pharma Ltd.: The company offers sovermol range of green polyols has been specially designed for use in coating, adhesive, and putty applications.
-
F. Hoffmann La Roche Ltd.: The company offers BiOH polyols and polymers which are soy-based industrial ingredients for polyurethane products such as flexible foam used in upholstered furniture, mattresses, and others.
-
Genentech Inc.: The company offers castor polyol 115 which is used in coating, construction, plastics, adhesives, and sealants industries.
-
GlaxoSmithKline Plc: The company offers Cardyon which is a polyether carbonate polyol for coatings, adhesives, and sealants applications.
Find additional highlights on the growth strategies adopted by vendors and their product offerings, Download Free Sample Report.
Related Reports
Stem Cell Umbilical Cord Blood (UCB) Market by End-user and Geography – Forecast and Analysis 2022-2026: The stem cell umbilical cord blood (UCB) market share is expected to increase by $ 1.47 bn from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 16.87%.
Lennox-Gastaut Syndrome Treatment Market by Type and Geography – Forecast and Analysis 2022-2026: The Lennox-Gastaut Syndrome (LGS) treatment market share is expected to increase by USD 684.75 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 4.42%.
|
Urticaria Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 10.35% |
|
Market growth 2022-2026 |
$1.31 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
9.75 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 41% |
|
Key consumer countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
|
Companies profiled |
Allakos Inc., Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, F. Hoffmann La Roche Ltd., Genentech Inc., GlaxoSmithKline Plc, Johnson and Johnson, Meiji Holdings Co. Ltd., Novartis AG, Otsuka Holdings Co. Ltd., Sanofi, TerSera Therapeutics LLC, Teva Pharmaceutical Industries Ltd., United BioPharma Inc., and Viatris Inc. |
|
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Application
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/usd-1-31-bn-growth-for-urticaria-drugs-market-through-2026-analysing-growth-for-pharmaceuticals—technavio-301635509.html
SOURCE Technavio
https://finance.yahoo.com/news/usd-1-31-bn-growth-083000847.html
